Multiple sclerosis (MS) is characterised by demyelinating plaques and the inability to remyelinate. This failure not only leads to symptoms due to acute demyelination but also worsens disability as a consequence of axonal degeneration. To this date, research has largely focused on preventing demyelination through immune-modulating therapies. While successful in reducing relapse rates, disease progression and cognitive decline continue. This has led to a paradigm shift towards therapies aimed at promoting remyelination. One promising approach involves modulating neuronal activity, as several in vitro and in vivo studies have shown a link between electrically active axons and myelination. However, these protocol are not easily translatable to people with MS. To address this limitation, our study explores the potential of tACS to enhance remyelination.